Chimeric Therapeutics Limited is an Australian biotechnology company specializing in the development of next-generation cell therapies for cancer treatment. As a clinical-stage enterprise, its main focus lies in the discovery, advancement, and eventual commercialization of chimeric antigen receptor T cell (CAR-T) therapies and natural killer (NK) cell therapies targeted at both solid tumors and blood cancers. The company’s pipeline notably features CHM 1101, a CAR-T therapy developed for difficult-to-treat solid tumors, and CHM CDH17, designed for advanced gastrointestinal cancers, both of which are currently in clinical trials. Additionally, Chimeric Therapeutics is advancing the CORE-NK platform—a ready-to-use, allogeneic NK cell therapy—which is under investigation for applications in acute myeloid leukemia and other malignancies. By integrating pioneering science with innovative clinical trial design, Chimeric Therapeutics seeks to expand access to advanced cellular immunotherapies, aiming to address significant unmet medical needs across oncology. Its mission places it at the forefront of therapeutic innovation within the healthcare sector, particularly in the rapidly evolving field of cancer immunotherapy.